Guillermo Villacampa

OncoDaily

News Feed Opinion Career Insight Dialogues Blog Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Guillermo Villacampa

Sep 1, 2024, 15:26 | Insight

Guillermo Villacampa: Meta-analysis evaluating immunotherapy in early breast cancer

Recently, an article by Guillermo Villacampa et al. was published in JAMA Oncology. "Neoadjuvant Immune…

Jul 29, 2024, 11:19 | Insight

Rasha Aboelhassan: We can give TDM1 in stage I HER2 positive breast cancer

Rasha Aboelhassan shared a post on LinkedIn about a recent paper by Paolo Tarantino et al., commenting:…

Jul 22, 2024, 20:26 | Insight

How tumor biology impacts Patritumab deruxtecan's efficacy in early breast cancer

Sonia Guedan, Cancer Immunologist at Hospital Clinic Barcelona, posted on X: "Our colleague Aleix Prat's…

Jul 20, 2024, 11:01 | Insight

Paolo Tarantino: Thanks to ESMO for featuring our 5-year analysis of the ATEMPT randomized phase 3 trial

Paolo Tarantino shared a post on LinkedIn about a paper titled "Adjuvant Trastuzumab Emtansine Versus…

Jul 5, 2024, 06:54 | Blog

Paolo Tarantino: Nearly 1000 downloads in less than a week for our ATEMPT 5-year publication

Paolo Tarantino, posted on X: "Nearly 1000 downloads in less than a week for our…

Jul 3, 2024, 12:06 | Insight

Guillermo Villacampa presents the HER2DX assay and its impact on survival outcomes

ESMO shared on LinkedIn: "For ESMO members: Breaking Science in breast cancer. Guillermo Villacampa presents…

Jul 1, 2024, 15:23 | Insight

Paolo Tarantino: Final analysis of the ATEMPT phase 2 trial

Paolo Tarantino shared a post on X: “Can ADCs help prevent recurrence from breast cancer…

May 18, 2024, 08:31 | Opinion

Guillermo Villacampa: Marleen Kok presents the ESMO Breast 24 key message in translation research

Paolo Tarantino shared the following post by Guillermo Villacampa, Biostatistician in the Oncology Data Science…

All: 8 Posts: 1 - 100